Company / R&D Expense
RHYTHM PHARMACEUTICALS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$167.3M
FY2025
5-year range
$104.1M / $238.0M
FY2021-FY2025
Trend
-29.7%
vs FY2024
Sector context
#98 of 210
Health Care
What the data says
At $167M, RHYTHM PHARMACEUTICALS, INC.'s r&d expense ranks #98 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $20M in FY2016 to $238M in FY2024.
Based on SEC 10-K filings.
$167M in FY2025 with a 5-year CAGR of +13.1%.
Improved from $135M to $167M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.5%
- 5-Year CAGR
- +13.1%
- 10-Year CAGR
- -
Sector benchmark
#98 of 210 in Health CareTop 47% of 210This company $167.3M Sector average $644.1M
▼
-74.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.1%, indicating consistent growth.
- In FY2025, r&d expense decreased 29.7% year-over-year.
- Ranks #98 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.3M | -29.7% |
| FY2024 | $238.0M | +76.3% |
| FY2023 | $135.0M | +24.2% |
| FY2022 | $108.6M | +4.3% |
| FY2021 | $104.1M | +15.1% |
| FY2020 | $90.5M | -17.4% |
| FY2019 | $109.5M | +117.4% |
| FY2018 | $50.3M | +119.9% |
| FY2017 | $22.9M | +16.8% |
| FY2016 | $19.6M | +174.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026